Metformin and sorafenib synergistically inhibit the proliferation of FLT3-ITD mutated leukemic cells.
Metformin synergistically sensitize FLT3-ITD-positive acute myeloid leukemia to sorafenib by inducing cell apoptosis and autophagy.
The anti-leukemic effect of metformin and sorafenib is, to some extent, mediated by the mTOR/p70S6K/4EBP1 pathway.